ArticleFrontiers in cardiovascular medicine2025
Construction of a competitive endogenous RNA network and identification of potential regulatory axes in hypertrophic cardiomyopathy.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiovascular disease, the pathogenesis of which remains unclear. In this study, we aimed to explore potential biomarkers and competitive endogenous RNA (ceRNA) network in HCM using integrated bioinformatics analysis. Methods: Three mRNA expression datasets relevant to HCM, along with one long non-coding RNA (lncRNA) dataset, were retrieved from the Gene Expression Omnibus database. Differential expression analysis was conducted using the "limma" package. Hub genes were subsequently explored through an integrated bioinformatics approach, which included weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) network construction, and feature selection methods. The expression levels and diagnostic accuracy of the candidate hub genes were validated in GSE141910. A ceRNA regulatory network was constructed by predicting interactions using miRDB, miRWalk, DIANA-LncBase, and lncRNASNP2 databases. Finally, immune cell infiltration analysis was performed to elucidate the immune landscape in HCM. Results: We intersected genes from three sources: 642 differentially expressed genes (DEGs) from GSE36961, 1,612 DEGs from GSE160997, and 2,930 genes from key WGCNA modules, yielding 162 common genes. A PPI network of these genes revealed 78 nodes, from which three pivotal clusters were identified. Feature selection methods converged on three hub genes (CD163, FCER1G, and CYP2J2), each demonstrating high diagnostic value. A ceRNA network was constructed, revealing five potential regulatory axes: SNHG1/miR-543/CD163, MEG8/miR-543/CD163, ZFAS1/miR-2110/FCER1G, SNHG14/miR-5001-5p/FCER1G, and TTN-AS1/miR-6740-3p/CYP2J2. Immune infiltration analysis indicated notable dysregulation of multiple immune cells in HCM, and the identified hub genes showed significant correlations with key immune subsets, including macrophages, regulatory T cells, and activated dendritic cells. Conclusion: Through integrated analysis, three hub genes linked to immune function (CD163, FCER1G, and CYP2J2) were discerned, and a corresponding ceRNA network was delineated. These results contribute to a renewed understanding of the pathogenic mechanisms in HCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.